abstract |
The present invention provides human IgG bispecific antibodies, wherein one arm of the antibody binds an epitope on immune effector cells, whilst the other arm targets CLEC12A or a functional equivalent thereof. Pharmaceutical uses of these antibodies against malignancies such as MDS, CML or AML are also provided. |